HOME > INVESTOR > ARCHIVES > PRESS RELEASE
December 2014
Lupin Receives Tentative Approval for Generic Prezista® Tablets
Date: Dec 30 Size: 112Kb
Lupin Receives FDA Approval for Generic Epivir® Tablets
Date: Dec 26 Size: 113Kb
Lupin Launches Authorized Generic for Celebrex® Capsules
Date: Dec 11 Size: 111Kb

 

November 2014
Lupin Receives FDA Approval for Generic Celebrex® Capsules
Date: Nov 03 Size: 111Kb

 

October 2014
Quarter II Results, FY 2014-15
Date: Oct 28 Size: 191Kb

 

September 2014
Lupin Announces Strategic Alliance for Emerging Markets
Date: Sept 16 Size: 144Kb
Lupin and Salix Announce Exclusive Distribution Agreement for Canada,
Zaxine®, Relistor® and Other Gastroenterology Products

Date: Sept 12 Size: 85Kb

 

August 2014
Lupin launches Basugine™
Date: Aug 06 Size: 90Kb

 

July 2014
Quarter I Results, FY 2014-15
Date: July 30 Size: 196Kb
Lupin Receives the 2014 ASTD BEST Award for Learning & Development
Date: July 16 Size: 133Kb

 

June 2014
Lupin Launches Generic Cipro® for Oral Suspension in the US
Date: June 18 Size: 108Kb

 

May 2014
Quarter IV & Annual Results, FY 2013-14 - Record Sales and Profits
Date: May 07 Size: 255Kb

 

April 2014
Lupin Inks Strategic Joint Venture Agreement with Yoshindo Inc.
Date: April 23 Size: 175Kb
Lupin Appoints Theresa Stevens as Chief Corporate Development Officer.
Date: April 21 Size: 155Kb
Lupin Receives FDA Approval for Generic Actos® Tablets.
Date: April 9 Size: 148Kb

 

March 2014
Lupin Acquires Laboratorios Grin S.A. De C.V., Mexico; Specialty Ophthalmic
Company; Enters the Latin American Market.

Date: March 27 Size: 128Kb
Lupin launches Generic Niaspan® Tablets in the US
Date: March 21 Size: 149Kb
Lupin Receives FDA Approval for Generic Monodox® Capsules and Cipro® for
Oral Suspension

Date: March 06 Size: 157Kb

 

February 2014
Lupin Receives FDA Approval for Generic Mycobutin® Capsules
Date: February 26 Size: 149Kb
Lupin Appoints Dr. Maurice Chagnaud as President-Europe & Head of
Inhalation Strategy

Date: February 18 Size: 167Kb
Lupin Acquires Nanomi B.V. Enters Complex Injectables Space
Date: February 03 Size: 153Kb
Strong Growth, Record Profits Quarter III Results, FY 2013-14 Net Sales up 21%;
EBITDA up 28%; Net profit up 42% Declares Interim Dividend of 150 %

Date: February 03 Size: 243Kb